Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Change in Acquisitions & Divestments: 2022-2024

Historic Change in Acquisitions & Divestments for Lineage Cell Therapeutics (LCTX) over the last 3 years, with Dec 2024 value amounting to $7.0 million.

  • Lineage Cell Therapeutics' Change in Acquisitions & Divestments was N/A to $2.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $9.0 million, marking a year-over-year change of. This contributed to the annual value of $7.0 million for FY2024, which is 88.95% down from last year.
  • As of FY2024, Lineage Cell Therapeutics' Change in Acquisitions & Divestments stood at $7.0 million, which was down 88.95% from $63.3 million recorded in FY2023.
  • Lineage Cell Therapeutics' Change in Acquisitions & Divestments' 5-year high stood at $63.3 million during FY2023, with a 5-year trough of $7.0 million in FY2024.
  • For the 3-year period, Lineage Cell Therapeutics' Change in Acquisitions & Divestments averaged around $26.0 million, with its median value being $7.7 million (2022).
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Change in Acquisitions & Divestments skyrocketed by 726.12% in 2023, and later slumped by 88.95% in 2024.
  • Lineage Cell Therapeutics' Change in Acquisitions & Divestments (Yearly) stood at $7.7 million in 2022, then soared by 726.12% to $63.3 million in 2023, then crashed by 88.95% to $7.0 million in 2024.